ArticleThe journal of headache and pain2013
New daily persistent headache with a thunderclap headache onset and complete response to nimodipine (a new distinct subtype of NDPH).
Article in The journal of headache and pain, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- New daily persistent headache: a systematic review on an enigmatic disorder.The journal of headache and pain · 2019Pooled it
- Headache Attributed to Reversible Cerebral Vasoconstriction Syndrome (RCVS).Diagnostics (Basel, Switzerland) · 2023Review
- The Enigma of New Daily Persistent Headache: What Solutions for Pediatric Age?Current pain and headache reports · 2022Review
- Update of New Daily Persistent Headache.Current pain and headache reports · 2022Review
- Post-reversible cerebral vasoconstriction syndrome headache.The journal of headache and pain · 2021Article
- Narrative Review: Headaches After Reversible Cerebral Vasoconstriction Syndrome.Current pain and headache reports · 2020Review
- Chronic headache with vasospasm treated with nimodipine.Journal of neurology · 2019Article
- New Daily Persistent Headache: a Diagnostic and Therapeutic Odyssey.Current neurology and neuroscience reports · 2019Review
- Resolution of new daily persistent headache by a tumor necrosis factor alpha antagonist, Venlafaxine.SAGE open medical case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At present new daily persistent headache is just a group of conditions that are connected based on the temporal profile of their mode of onset. If new daily persistent headache is a true distinct syndrome like migraine then we need to start to define subtypes that have specific effective treatments such has been noted for migraine sub-forms. We present what we believe is the first recognized subtype of new daily persistent headache that which starts with a thunderclap headache onset. A patient presented with a 13 month history of a daily headache from onset which initiated as a thunderclap headache along with persistent acalculia. All neuroimaging studies for secondary causes were negative. Nimodipine rapidly and completely alleviated her headache and associated neurologic symptoms. We propose that this subtype of new daily persistent headache is caused by a very rapid increase in CSF tumor necrosis factor alpha levels leading to cerebral artery vasospasm with a subsequent thunderclap headache, then continuous or near continuous cerebral artery vasospasm leading to a persistent daily headache. Nimodipine which not only inhibits cerebral artery vasospasm but also tumor necrosis factor alpha production appears to be a specific treatment for this distinct subtype of new daily persistent headache.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.